| Ticker: OPSI | 7615 Golden Triangle Drive, Suite A | |
| Exchange: NASDAQ-National Market | Minneapolis, Minnesota 55344 | |
| Industry: Manufacturing | (612) 944-5857 |
| Type of Shares: | Common Shares | Filing Date: | 12/1/95 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 2/14/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $13.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.91 | |
| Offering Amount: | $30,000,000 | Selling: | $0.52 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,877,417 |
| Manager | Tier | Phone |
| Alex. Brown & Sons Incorporated | Lead Manager | (410) 727-1700 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 576-3423 |
| Volpe, Welty & Company | Co-manager | (415) 956-8120 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $0.00 | Assets: | $6.37 | ||
| Net Income: | -$8.13 | Liabilities: | $0.59 | ||
| EPS: | -$1.05 | Equity: | $5.78 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company has developed the SensiCath system, a patient attached, on demand arterial blood gas monitoring system, which provides precise and accurate results within 60 seconds without removing blood from the patient. The company believes that the SensiCath System is the first analyzer that will be integrated into both an arterial pressure monitoring line and a critical care patient monitoring system. The SensiCath system utilizes a disposable, fiber optic sensor device connected to a small modular instrument that can be configured to integrate with bedside monitoring systems or to serve as a standalone monitor. Arterial blood gas tests measure oxygen, carbon dioxide and acid-base in a sample of blood taken from a patient's artery. These three parameters are the front line indicators of the patient's ability to absorb and use oxygen and as such are the most frequently requested and urgently needed diagnostic tests for medically unstable patients in intensive care units and operating rooms. |
| Use of Proceeds |
| The company intends to use approximately $6.9 million of the net proceeds to fund sales and marketing activities relating to the launch of the SensiCath System, approximately $3.1 million to expand manufacturing capacity, approximately $13.4 million to fund development of additional configurations of the SensiCath System and other research and development programs and the remainder for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.